Pharmaceuticals - Community Register


Community list of not active orphan medicinal products


Product information

Eltrombopag olamine

EU orphan designation number: EU/3/07/467
Active ingredient: Eltrombopag olamine
Indication: Treatment of idiopathic thrombocytopenic purpura
Sponsor: GlaxoSmithKline Trading Services Limited
6900 Cork Airport Business Park, Kinsale Road , Cork, Ireland
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Revolade on 11/03/2010 with the number EU/1/10/612

   Public summary of scientific opinion     EPAR


European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
07/08/2007 Centralised Orphan - Designation EMEA/OD/031/07 (2007)3839 of 03/08/2007
06/08/2008 Centralised Orphan - Transfer of orphan designation EMEA/OD/031/07/T/01 (2008)4330 of 04/08/2008
09/12/2011 Centralised Orphan - Removal of orphan designation from Community Register